OakChart

Opko Health Inc

OPKHealthcare·Diagnostics & Research·USA·Small·NASD·Nov 11 • 3:59 PM ET

1.710.00 (0.00%)
2026-11-12 00:01 CET
Market cap
1,269.69 USD m
Revenue, TTM
501.64 USD m
Net income, TTM
-148.06 USD m
Free cash flow, TTM
-135.34 USD m
EPS diluted, TTM
-0.20
P/E
-
Compare

Price

OPK against its 20, 50 and 200-day averages
2050200beatmiss
1.201.401.601.8027.7M55.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OPKclose 1.7120-day 1.6650-day 1.60200-day 1.361.7152w high

8.1% under the 52-week high of 1.86 on 6 Nov 2026. 52-week low 0.98 on 29 Apr 2026. Last 15 sessions, 17.7% high to low

Volume 0.70× normal · the line is the 50-bar volume average

Profile

OPK
52-week range, 83% of the way up
0.981.86

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment manages the clinical laboratory operations of BioReference. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and their global pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

IndexRUT
Employees2275
IPONov 02, 1995
Beta1.52
ATR, 14d0.09
Rel volume0.70
Short float8.60%
Insider own48.59%
Inst own28.95%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.27B
Enterprise Value1.40B
Income-148.06M
Sales501.64M
Book/sh1.57
Cash/sh0.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2275
IPONov 02, 1995

Ratios

P/E-
Forward P/E-
PEG-
P/S2.53
P/B1.09
P/C3.25
P/FCF-
EV/EBITDA-
EV/Sales2.78
Quick Ratio4.65
Current Ratio4.97
Debt/Eq0.46
LT Debt/Eq0.44
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.20
EPS next Y-0.29
EPS next Q-0.06
EPS this Y28.44%
EPS next Y-32.79%
EPS next 5Y0.33%
EPS past 3/5Y13.03% -
Sales past 3/5Y-15.45% -15.82%
EPS Y/Y TTM18.50%
Sales Y/Y TTM-21.87%
EPS Q/Q-358.84%
Sales Q/Q-56.87%
EarningsNov 04 AMC
EPS/Sales Surpr.26.47% -52.13%

Ownership

Insider Own48.59%
Insider Trans-0.00%
Inst Own28.95%
Inst Trans1.68%
ROA-6.71%
ROE-10.74%
ROIC-9.20%
Gross Margin31.58%
Oper. Margin-29.06%
Profit Margin-29.51%
SMA202.80%
SMA506.79%
SMA20025.71%
Trades-

Technical

Shs Outstand711.66M
Shs Float381.75M
Short Float8.60%
Short Ratio8.74
Short Interest32.85M
52W High1.86 -8.06%
52W Low0.98 75.04%
Volatility5.99% 5.92%
ATR (14)0.09
RSI (14)58.99
Beta1.52
Rel Volume0.70
Avg Volume3.76M
Volume2,648,105

Performance

Perf Week-3.39%
Perf Month29.55%
Perf Quarter22.14%
Perf Half Y54.05%
Perf YTD35.71%
Perf Year28.57%
Perf 3Y35.71%
Perf 5Y-58.19%
Perf 10Y-81.90%
Recom1.33
Target Price4.15
Prev Close1.71
Price1.71
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026UpgradeBBarrington ResearchMkt Perform → Outperform$2.25+31.6%
Apr 29, 2026DowngradeBBarrington ResearchOutperform → Mkt Perform
Nov 20, 2025InitiatedJJP MorganNeutral
Oct 31, 2025DowngradeJJefferiesBuy → Hold$1.60-6.4%
Apr 25, 2025InitiatedJJP MorganNeutral
Jun 29, 2023UpgradeBBarrington ResearchMkt Perform → Outperform$2+17.0%
Dec 15, 2022InitiatedHH.C. WainwrightBuy$3+75.4%
Jan 24, 2022DowngradeBBarrington ResearchOutperform → Mkt Perform
Jun 21, 2021InitiatedLLadenburg ThalmannBuy$7+309.4%
Nov 25, 2019InitiatedPPiper JaffrayOverweight$2.50+46.2%

Peers

Mkt cap
TickerCompanyMkt cap
DGXQuest Diagnostics Inc28.46B
FLGTFulgent Genetics Inc718.03M
LHLabcorp Holdings Inc30.23B
NEONeogenomics Inc2.18B
MYGNMyriad Genetics Inc548.68M
MDXHMDxHealth SA13.98M
XGNExagen Inc121.98M
ARDXArdelyx Inc786.79M
ASNDAscendis Pharma A/S17.03B
PFEPfizer Inc167.86B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PAGANELLI JOHN ADirectorNov 05 '26Sale1.829,17516,6980Nov 05 04:07 PM
PAGANELLI JOHN ADirectorNov 05 '26Sale1.784,4267,878389,914Nov 05 04:07 PM
PAGANELLI JOHN ADirectorMar 20 '26Buy1.1410,00011,350394,340Mar 20 04:25 PM
FROST PHILLIP MD ET ALCEO & ChairmanNov 21 '25Buy1.33580,000768,807216,706,448Nov 21 05:07 PM
FROST PHILLIP MD ET ALCEO & ChairmanNov 20 '25Buy1.33580,000771,328216,126,448Nov 20 06:10 PM
FROST PHILLIP MD ET ALCEO & ChairmanNov 19 '25Buy1.31580,000759,115215,546,448Nov 19 05:02 PM
FROST PHILLIP MD ET ALCEO & ChairmanNov 18 '25Buy1.27533,300678,906214,966,448Nov 18 05:18 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.050-0.068-0.07065.40136.625
2026Q22026-07-27-0.010-0.080-0.011163.5131.236
2026Q12026-04-28-0.070-0.070-0.072124.2130.517
2025Q42026-02-26-0.040-0.069-0.041148.5139.767
2025Q32025-10-290.030-0.0600.028151.7160.785
2025Q22025-07-31-0.190-0.113-0.188156.8165.76
2025Q12025-04-30-0.100-0.069-0.101149.9164.267
2024Q42025-02-270.010-0.0930.015183.6155.426
2024Q32024-11-070.030-0.0930.025173.6181.536
2024Q22024-08-07-0.010-0.095-0.015182.2184.76
2024Q12024-05-07-0.120-0.095-0.116173.7182.996
2023Q42024-02-27-0.090-0.100-0.089181.9177.536
2023Q32023-11-06-0.110-0.100-0.112178.6174.786
2023Q22023-08-03-0.030-0.072-0.026265.4201.976
2023Q12023-05-03-0.020-0.077-0.024237.6193.356
2022Q42023-02-23-0.110-0.112-0.114185.4168.216

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.530-0.435-0.529901.9893.7
2020FY0.0500.0260.0481,4351,380
2021FY-0.0500.044-0.0471,7751,703
2022FY-0.460-0.442-0.4571,004986.82
2023FY-0.250-0.260-0.251863.5859.13
2024FY-0.080-0.180-0.077713.1684.92
2025FY-0.300-0.347-0.293606.9598.1
2026FY--0.215--420.6
2027FY--0.285--314.25
2028FY--0.297--383.86
2029FY--0.200--651.4
2030FY--0.190--700.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0660580.1965.76143.1
2026Q4S2026-11-0560493.4066.90145
2026Q4S2026-11-04600145.48143.1148.5
2026Q4S2026-10-14600145.48143.1148.5
2026Q4S2026-10-11601145.48143.1148.5
2026Q4S2026-07-31641145.48143.1148.5
2026Q4S2026-07-28640146.15143.1149
2026Q4S2026-07-13600140.55126.2149
2026Q4S2026-06-25612140.55126.2149
2026Q4S2026-05-13722141.66126.2149
2026Q4S2026-04-29742141.66126.2149
2026Q4S2026-02-27711141.66137.2144
2026Q4S2026-01-13400142.25139.5145.5
2026Q4S2025-11-11404142.25139.5145.5

Estimate history

EPS, annual-0.546-0.272-0.5290.048-0.047-0.457-0.251-0.077-0.3-0.196
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0250.015-0.101-0.1880.028-0.041-0.072-0.011-0.072
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual966.006990.266901.9351435.4131774.7181004.196863.495713.142606.879501.64
Period201720182019202020212022202320242025TTM
Sales, quarterly173.632183.6149.952156.807151.669148.45124.196163.5865.414
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual559.474586.332669.829670.036681.427772.651773.282671.551759.068711.657
Period201720182019202020212022202320242025MRQ
Shares, quarterly682.483671.551671.607779.783768.702759.068755.093745.953711.657
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue501.64606.88713.14863.501,004.201,774.721,435.41901.93990.27
Cost of Goods Sold Incl. D&A343.23478.83577.27631.40799.701,237.01946.41637.27672.57
Gross Profit158.41128.05135.88232.09204.49537.71489.00264.67317.70
Selling, General and Administrative Excl. Other304.20347.04409.43390.15446.56545.71430.89461.18483.93
Research and Development127.31124.03105.2189.5973.8976.8575.32117.87125.59
Other Operating Expense0.000.000.000.004.066.464.390.000.00
Operating Income-145.78-218.99-273.56-158.06-246.12-14.4653.73-196.51-166.24
Interest Expense47.08108.4647.4713.5112.0618.8821.9321.5211.89
Unusual Expense-3.530.676.310.28152.5213.38-4.0477.371.92
Net Income Before Taxes-159.12-241.36-10.36-184.32-391.52-14.0348.68-304.96-177.27
Income Taxes-34.06-15.7142.844.44-63.5015.4917.627.06-38.73
Consolidated Net Income-130.08-225.68-53.22-188.86-328.40-30.1430.59-314.93-153.04
Net Income From Continuing Operations-130.08-225.68-53.22-188.86-328.40-30.1430.59-314.93-153.04
Net Income-148.06-225.68-53.22-188.86-328.40-30.1430.59-314.93-153.04
EPS (Recurring)-0.20-0.30-0.07-0.25-0.31-0.030.04-0.44-0.27
EPS (Basic, Before Extraordinaries)-0.20-0.30-0.08-0.25-0.46-0.050.05-0.53-0.27
EPS (Diluted)-0.20-0.30-0.08-0.25-0.46-0.050.05-0.53-0.27
EBITDA-59.86-127.36-175.38-52.76-137.4764.25139.09-102.70-68.89
Non-Operating Income (Expense)30.2186.75316.98-12.4819.1832.6912.85-9.572.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.648.458.739.0214.629.956.5010.6017.19
Price To Earnings Ratio------82.81--
Price To Sales Ratio2.401.561.431.310.901.761.760.971.71
Gross Margin31.5821.1019.0526.8820.3630.3034.0729.3432.08
Operating Margin-29.06-36.08-38.36-18.30-24.51-0.813.74-21.79-16.79
Net Margin-29.51-37.19-7.46-21.87-32.70-1.702.13-34.92-15.45
Shares Outstanding711.66759.07671.55773.28772.65681.43670.04669.83586.33
Market Capitalization1,269.691,269.691,003.251,167.32965.863,277.252,646.50978.431,685.08

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue65.41163.58124.20148.45151.67156.81149.95183.60
Cost of Goods Sold Incl. D&A39.81102.5397.41103.48121.31126.85127.19119.30
Gross Profit25.6161.0526.7944.9730.3629.9622.7664.30
Selling, General and Administrative Excl. Other57.0186.0977.8183.2983.8889.9489.9397.40
Research and Development32.1833.1729.2032.7730.0830.3430.8430.40
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-31.41-25.04-51.02-38.32-53.52-59.98-67.17-33.10
Interest Expense13.4511.3810.9411.3111.3670.3315.4714.24
Unusual Expense-4.33-2.363.94-0.78-0.29-0.312.05-19.83
Net Income Before Taxes-37.87-13.40-60.96-46.9041.43-162.52-73.3734.90
Income Taxes-7.31-4.98-6.11-15.6619.80-14.08-5.7720.90
Consolidated Net Income-35.56-8.42-54.85-31.2621.63-148.44-67.6114.00
Net Income From Continuing Operations-35.56-8.42-54.85-31.2621.63-148.44-67.6114.00
Net Income-53.53-8.42-54.85-31.2621.63-148.44-67.6114.00
EPS (Recurring)-0.08-0.01-0.07-0.040.03-0.19-0.100.00
EPS (Basic, Before Extraordinaries)-0.07-0.01-0.07-0.040.03-0.19-0.100.02
EPS (Diluted)-0.07-0.01-0.07-0.040.03-0.19-0.100.01
EBITDA-12.47-2.63-28.82-15.94-30.78-36.95-43.68-9.06
Non-Operating Income (Expense)2.6620.664.941.95106.02-32.5211.3162.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.421.772.162.292.371.752.072.42
Price To Sales Ratio2.401.931.491.591.881.571.621.96
Gross Margin39.1437.3221.5730.2920.0219.1115.1835.02
Operating Margin-48.02-15.31-41.08-25.81-35.29-38.25-44.79-18.03
Net Margin-81.84-5.14-44.16-21.0614.26-94.66-45.097.63
Shares Outstanding711.66745.95755.09759.07768.70779.78671.61671.55
Market Capitalization1,269.691,132.64865.34967.301,230.361,046.831,114.771,003.25

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments369.07431.9495.88153.19134.7172.2185.4596.4791.50
Short Term Receivables126.12152.05130.20148.61265.59302.26157.69161.98187.05
Inventories65.8256.8065.7074.0686.50132.3453.4342.3049.33
Other Current Assets20.8721.3117.7018.67336.2116.3727.4716.9820.98
Total Current Assets581.88662.09309.48394.52823.01523.18324.05317.73348.86
Net Property, Plant & Equipment120.86124.14143.52121.60123.95178.29166.49144.67146.56
Total Investments and Advances14.1754.5816.0828.0810.7315.7320.7531.2340.64
Intangible Assets1,195.571,340.871,533.541,614.371,432.481,745.801,791.101,950.222,048.28
Deferred Tax Assets----4.30----
Other Assets19.4718.549.088.685.2310.066.897.225.62
Total Assets1,931.942,200.212,011.702,167.262,399.722,473.062,309.272,451.072,589.96
Short Term Debt Incl. Current Port. of LT Debt22.8629.3543.1251.0328.5836.1824.4040.6915.32
Accounts Payable41.1047.0769.6866.9982.04100.8862.5447.4074.31
Income Tax Payable3.6022.271.38----3.234.61
Other Current Liabilities79.1294.4085.8895.46219.39238.42162.18197.00217.79
Total Current Liabilities146.68193.10200.05213.48330.01375.48249.12288.32312.03
Long Term Debt373.92475.10283.45254.52226.18258.39291.57172.77142.66
Provision for Risks Charges5.5414.270.006.975.554.517.3122.1629.60
Deferred Tax Liabilities126.24140.80126.77126.43148.49137.21118.72115.19148.73
Other Liabilities11.6011.5012.214.214.3625.9227.8061.33113.31
Total Liabilities663.99834.76622.48605.61714.59801.51694.51659.78746.33
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,267.961,365.451,389.221,561.651,685.131,671.551,614.761,791.291,843.62
Total Shareholders Equity1,267.961,365.451,389.221,561.651,685.131,671.551,614.761,791.291,843.62
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,267.961,365.451,389.221,561.651,685.131,671.551,614.761,791.291,843.62
Total Liabilities & Stockholders Equity1,931.942,200.212,011.702,167.262,399.722,473.062,309.272,451.072,589.96
Book Value Per Share1.672.031.802.022.472.492.413.063.30
Tangible Book Value Per Share0.100.04-0.19-0.070.37-0.11-0.26-0.27-0.37
Full-Time Employees2,2752,9973,9304,1965,7675,2696,0965,6906,030
Price to Book Ratio1.090.710.810.591.951.580.610.991.31
Return on Assets-10.92-2.53-9.04-14.38-1.241.28-13.23-6.08-11.40
Return on Equity-17.14-3.86-12.80-20.23-1.801.86-18.49-8.32-15.51
Return on Invested Capital-13.75-2.89-11.29-18.08-1.581.58-16.52-7.79-15.37
Quick Ratio3.523.131.221.502.231.041.090.960.96
Current Ratio3.973.431.551.852.491.391.301.101.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-148.06-225.68-53.22-188.86-328.40-30.1430.59-314.93-153.04
Depreciation89.7191.6398.18105.30108.6678.7285.3693.8197.34
Other Funds (Non Cash)-22.6111.69-275.3633.42156.310.095.50113.0839.83
Funds from Operations-115.31-137.36-215.66-50.00-137.8458.82137.09-103.72-51.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-9.73-41.1832.1721.8042.65-20.48-97.61-68.81-58.14
Cash from Operating Activities-125.05-178.54-183.49-28.20-95.1938.3439.48-172.52-109.14
Capital Expenditures-10.79-12.28-25.01-16.27-24.58-32.16-33.68-12.74-27.86
Net Assets From Acquisitions0.000.000.000.00-1.76-4.000.000.000.00
Sale of Fixed Assets and Businesses38.45198.06210.622.711.9566.030.240.671.22
Purchase or Sale of Investments-4.6744.52166.60-4.64115.426.0815.11-1.200.52
Purchase of Investments-5.20-7.670.00-5.000.00-2.000.00-1.20-1.00
Sale Or Maturity of Investments0.5352.18166.600.36115.428.0815.110.001.52
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities22.98230.30352.21-18.2091.0435.95-18.33-13.27-26.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-43.32-47.30-90.43-0.27-0.771.080.7676.0693.67
Repurchase of Common Pref Stock-41.93-47.04-90.22-0.27-0.770.000.00-0.000.00
Sale of Common Pref Stock-1.39-0.26-0.210.000.001.080.7676.0693.67
Proceedsfrom Stock Options-1.39-0.26-0.210.000.000.000.0076.0692.50
Issuance or Reduction of Debt, Net121.27-70.76274.60-11.0323.75-11.43-35.8399.1947.24
Change in Long Term Debt121.27-70.76274.60-11.0323.75-11.43-35.8399.1947.24
Issuance of Long Term Debt161.7833.03926.05671.681,059.521,684.531,107.87487.3181.92
Reduction of Long Term Debt-40.51-103.79-651.45-682.71-1,035.77-1,695.96-1,143.70-388.12-34.68
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-----
Cash from Financing Activities77.94-118.06184.17-11.3022.97-10.35-35.08175.25140.91
Exchange Rate Effect-1.543.43-3.160.39-0.34-1.440.69-0.48-0.68
Net Change in Cash-25.66-62.87349.73-57.3118.4862.50-13.24-11.024.97
Free Cash Flow-135.34-190.82-208.50-44.47-119.776.185.79-185.26-137.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----504.33436.76--
Deferred Taxes & Investment Tax Credit--15.0014.740.15-74.4110.1615.644.32-35.13

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments390.22300.76341.88369.07415.20271.72
Short Term Receivables94.92114.91107.62126.12124.38134.58
Inventories50.6061.8564.4065.8264.9566.34
Other Current Assets270.5422.7121.4620.8722.60110.69
Total Current Assets806.28500.24535.36581.88627.13583.33
Net Property, Plant & Equipment101.91115.42118.39120.86120.67121.56
Total Investments and Advances44.5040.2210.5314.1713.3713.04
Intangible Assets908.531,154.081,173.621,195.571,214.411,235.17
Other Assets19.0419.4918.9019.4719.9319.87
Total Assets1,880.251,829.451,856.801,931.941,995.511,972.99
Short Term Debt Incl. Current Port. of LT Debt21.9222.9522.2622.8624.3525.51
Accounts Payable47.9250.0444.1841.1050.8356.68
Income Tax Payable8.976.434.633.6010.459.61
Other Current Liabilities83.5569.9477.3279.1283.7079.38
Total Current Liabilities162.36149.37148.38146.68169.32171.18
Long Term Debt493.73375.13374.67373.92371.07370.23
Provision for Risks Charges0.001.183.195.547.559.90
Deferred Tax Liabilities96.67108.23114.56126.24130.34113.33
Other Liabilities11.3111.3911.3811.6011.7311.44
Total Liabilities764.08645.29652.19663.99690.02676.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,116.171,184.171,204.611,267.961,305.491,296.90
Total Shareholders Equity1,116.171,184.171,204.611,267.961,305.491,296.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,116.171,184.171,204.611,267.961,305.491,296.90
Total Liabilities & Stockholders Equity1,880.251,829.451,856.801,931.941,995.511,972.99
Book Value Per Share1.571.591.601.671.701.66
Tangible Book Value Per Share0.290.040.040.100.120.08
Full-Time Employees---2,275--
Price to Book Ratio1.090.940.680.740.930.68
Return on Assets-6.71-3.83-10.69-10.92-8.49-8.96
Return on Equity-10.74-5.88-16.92-17.14-13.32-13.16
Return on Invested Capital-3.33-0.54-3.47-1.901.29-8.90
Quick Ratio4.652.933.173.523.323.02
Current Ratio4.973.353.613.973.703.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-53.53-8.42-54.85-31.2621.63-148.44
Depreciation22.7322.4122.2022.3722.7423.03
Other Funds (Non Cash)5.56-42.629.215.24-95.4295.58
Funds from Operations-35.30-34.89-31.33-13.79-32.77-45.55
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.02-8.6112.02-12.13-1.88-37.87
Cash from Operating Activities-36.31-43.50-19.31-25.92-34.65-83.42
Capital Expenditures-3.29-3.00-1.83-2.67-3.13-3.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses19.7918.540.030.09197.780.11
Purchase or Sale of Investments-5.200.000.000.530.000.34
Purchase of Investments-5.200.000.000.000.000.34
Sale Or Maturity of Investments0.000.000.000.530.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.2915.54-1.80-2.05194.65-2.83
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-11.55-13.36-4.77-13.64-15.28-18.47
Repurchase of Common Pref Stock-10.63-13.02-4.77-13.51-15.28-18.25
Sale of Common Pref Stock-0.92-0.340.00-0.130.00-0.21
Proceedsfrom Stock Options-0.92-0.340.00-0.130.00-0.12
Issuance or Reduction of Debt, Net126.020.33-0.39-4.70-0.93-61.02
Change in Long Term Debt126.020.33-0.39-4.70-0.93-61.02
Issuance of Long Term Debt134.5910.188.498.537.8711.03
Reduction of Long Term Debt-8.56-9.85-8.88-13.23-8.80-72.05
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities114.47-13.03-5.16-18.34-16.21-79.49
Exchange Rate Effect-0.66-0.14-0.910.17-0.321.46
Net Change in Cash88.78-41.13-27.18-46.13143.48-164.28
Free Cash Flow-39.10-46.50-21.14-28.59-37.78-86.70

Revenue breakdown

Product2024: 155.11M 2025: 156.92M
Service2024: 480.67M 2025: 370.28M
Transfer of Intellectual Property and Other2024: 77.36M 2025: 79.68M
Chile2024: 65.05M
Ireland2024: 48.40M
Israel2024: 1.77M
Mexico2024: 23.87M
Other Countries2024: 3.12M
Spain2024: 24.63M
United States2024: 546.30M 2025: 606.88M
Diagnostics2024: 480.67M
Pharmaceutical2024: 232.48M
Total Pharmaceutical Preparations revenue2025: 606.88M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.60%32.8M381.8M3.56M
2026-10-158.86%34.0M383.7M4.04M
2026-09-309.27%35.6M383.7M3.37M
2026-09-159.38%36.0M383.7M3.59M
2026-08-319.49%34.6M364.0M3.47M
2026-08-149.24%33.6M364.0M3.56M
2026-07-318.92%32.9M368.5M3.43M
2026-07-159.03%33.6M372.7M2.78M
2026-06-308.75%32.6M372.7M2.66M
2026-06-158.74%32.8M375.3M2.58M
2026-05-298.76%33.0M377.3M2.50M
2026-05-158.66%32.7M377.3M2.36M
2026-04-308.95%33.8M377.3M2.51M
2026-04-158.70%33.0M379.3M2.67M
2026-03-318.69%33.6M386.7M2.88M
2026-03-138.48%32.8M386.7M3.13M
2026-02-278.11%31.4M386.7M3.18M
2026-02-138.10%31.7M391.1M3.32M
2026-01-307.90%30.9M391.1M3.32M
2026-01-157.80%30.5M391.1M2.97M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.851.601.1219.69357.000.000.956-0.0090.000
call1.000.201.150.709.9263890.000.904-0.0090.000
call1.500.100.400.242.8573291000.774-0.0060.001
call2.000.000.050.051.3321,0150.000.259-0.0070.001
call2.500.000.050.032.43011.000.000.176-0.0090.001
call5.000.003.400.004.4090.000.000.113-0.0130.001
call7.500.003.400.005.6560.000.000.101-0.0140.000
put0.500.000.450.026.64549.000.00-0.044-0.0090.000
put1.000.000.300.013.30011.000.00-0.096-0.0080.000
put1.500.000.050.041.79392.000.00-0.275-0.0080.001
put2.000.000.800.455.8160.000.00-0.741-0.0060.001
put2.500.451.200.005.9450.000.00-0.820-0.0090.001
put5.001.203.503.426.6411.000.00-0.887-0.0120.001
put7.503.707.900.000.0000.000.00-0.902-0.0140.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13D/ASEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-158-KCurrent report2026-10-14SEC
2026-10-028-KCurrent report2026-09-30SEC
2026-08-2810-Q/A2026-06-30SEC
2026-08-2810-Q/A2026-03-31SEC
2026-08-148-KCurrent report2026-08-13SEC
2026-08-07SCHEDULE 13DSEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-2710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-07-01SCHEDULE 13D/ASEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-05-15DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-288-KCurrent report2026-04-28SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110024.58K2
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0311.35K100
2026-020000
2026-010000
2025-120000
2025-112.98M400

Institutional holders

Manager% owned
Rubric Capital Management LP6.33%
BlackRock, Inc.4.90%
VANGUARD CAPITAL MANAGEMENT LLC1.98%
VANGUARD PORTFOLIO MANAGEMENT LLC1.98%
GEODE CAPITAL MANAGEMENT, LLC1.48%
STATE STREET CORP1.37%
GOLDMAN SACHS GROUP INC0.93%
Whitefort Capital Management, LP0.60%
NORTHERN TRUST CORP0.50%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC0.48%

Funds

Fund% owned
iShares Russell 2000 ETF1.39%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.29%
VANGUARD SMALL-CAP INDEX FUND0.92%
VANGUARD EXTENDED MARKET INDEX FUND0.65%
Fidelity Small Cap Index Fund0.58%
iShares Russell 2000 Value ETF0.51%
iShares Biotechnology ETF0.35%
VANGUARD RUSSELL 2000 INDEX FUND0.31%
VANGUARD SMALL-CAP VALUE INDEX FUND0.29%
Schwab U.S. Small-Cap ETF0.27%

OakChart. OPK. Cached 15 minutes.